全文获取类型
收费全文 | 15067篇 |
免费 | 987篇 |
国内免费 | 316篇 |
专业分类
耳鼻咽喉 | 33篇 |
儿科学 | 434篇 |
妇产科学 | 130篇 |
基础医学 | 2235篇 |
口腔科学 | 108篇 |
临床医学 | 769篇 |
内科学 | 2092篇 |
皮肤病学 | 100篇 |
神经病学 | 80篇 |
特种医学 | 93篇 |
外国民族医学 | 1篇 |
外科学 | 370篇 |
综合类 | 1243篇 |
现状与发展 | 1篇 |
一般理论 | 2篇 |
预防医学 | 6812篇 |
眼科学 | 32篇 |
药学 | 1059篇 |
4篇 | |
中国医学 | 40篇 |
肿瘤学 | 732篇 |
出版年
2024年 | 8篇 |
2023年 | 504篇 |
2022年 | 642篇 |
2021年 | 868篇 |
2020年 | 701篇 |
2019年 | 607篇 |
2018年 | 648篇 |
2017年 | 570篇 |
2016年 | 604篇 |
2015年 | 683篇 |
2014年 | 786篇 |
2013年 | 1164篇 |
2012年 | 841篇 |
2011年 | 972篇 |
2010年 | 795篇 |
2009年 | 769篇 |
2008年 | 471篇 |
2007年 | 642篇 |
2006年 | 553篇 |
2005年 | 485篇 |
2004年 | 456篇 |
2003年 | 406篇 |
2002年 | 315篇 |
2001年 | 290篇 |
2000年 | 244篇 |
1999年 | 231篇 |
1998年 | 153篇 |
1997年 | 163篇 |
1996年 | 114篇 |
1995年 | 81篇 |
1994年 | 68篇 |
1993年 | 65篇 |
1992年 | 47篇 |
1991年 | 55篇 |
1990年 | 50篇 |
1989年 | 56篇 |
1988年 | 42篇 |
1987年 | 33篇 |
1986年 | 35篇 |
1985年 | 52篇 |
1984年 | 27篇 |
1983年 | 15篇 |
1982年 | 16篇 |
1981年 | 12篇 |
1980年 | 5篇 |
1979年 | 6篇 |
1978年 | 8篇 |
1977年 | 3篇 |
1976年 | 2篇 |
1974年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 453 毫秒
51.
Patient experience with, and use of, an electronic monitoring system to assess vaccination responses
Stuart S. Olmsted PhD John D. Grabenstein RPh PhD † Arvind K. Jain MS ‡ Nicole Lurie MD MSPH § 《Health expectations》2006,9(2):110-117
OBJECTIVE: To evaluate the user experience and acceptability of an electronic patient monitoring system. SETTING AND PARTICIPANTS: 822 Military and civilian personnel at a health clinic at a major US military headquarters used an Internet and telephone-based electronic monitoring system to report vaccination-site responses and symptoms after receiving the smallpox vaccination. Focus groups of vaccinees were conducted to help develop a survey about the experience that was distributed to 379 vaccinees (96% completion rate). RESULTS: Users of the electronic monitoring system reported that it was fast and easy to use and reported they would use a system like this again and recommend an electronic monitoring system to a friend or relative. Most users (84%) were comfortable with a physician tracking their vaccine reaction using their electronic reports, but only half (51%) were comfortable with eliminating the post-vaccination follow-up visit with their health-care provider based on their electronic reports. CONCLUSIONS: This electronic monitoring system was well received by vaccinees and allowed health-care providers to track the status of vaccinees. However, vaccinees were not comfortable replacing a physician visit with electronic monitoring, at least for the smallpox vaccination. A monitoring system like this may be useful in public health settings, such as mass vaccination or prophylaxis during a bioterrorism event, a pandemic influenza outbreak, or another public health emergency. 相似文献
52.
目的:考核HFRS地鼠肾细胞Ⅱ型灭活疫苗的安全性、免疫法及其流行病学效果。方法:采用间接免疫荧光抗体试验(IFA)、微量细胞变性中和试验(MCPENT),检测接种者血中荧光抗体及中和抗体水平;调查接种组与对照组发病情况。结果:以怀宁、广德两县18个村为疫苗观察现场,接种组7499人,对照组7261人,中强反应率为224%(5/223)。3针全程免疫后中和抗体阳转率为63.33%(19/30),荧光抗体阳转率为38.58%(27/70);接种后1年内接种组无发病,对照组发病3例。结论:该疫苗的安全性较好;有一定水平的免疫应答,但防病效果应进一步观察确证。 相似文献
53.
Macrophages, dendritic cells or B lymphocytes have been shownto play a major role in the presentation of soluble antigensto CD4+ T cells. In contrast, the capacity of these cells topresent particulate antigens such as bacterial or parasiticantigens to T cells remains controversial. To investigate thisquestion, well defined particulate antigens were prepared bycovalent linkage of proteins or peptides to 1 µm in diametersynthetic microspheres. The T cell immunogenicity of such particulateantigens was analyzed in vitro and in vivo. In vitro, a solubleprotein such as hen egg lysozyme (HEL) coupled to beads stimulateda strong proliferative T cell response of lymph node cells fromHEL-primed mice or of specific T cell hybridomas. HEL coupledto beads was presented to the specific T cell hybridomas bysplenocytes or by peritoneal macrophages, but not by lymphomaB cells. Immunization of mice with several different proteinantigens or with a synthetic peptide covalently linked to beadsinduced strong CD4+ T cell responses in the absence of adjuvant.The strong in vivo immunogenicity of proteins coupled to beadsdid not result from a non-specific adjuvant effect of beadssince covalent linkage of the antigen to beads was strictlyrequired to induce T cell responses in the absence of adjuvant.In vivo treatment by carrageenan showed that macrophages arerequired for the in vivo stimulation of T cell responses bythese particulate antigens. Thus, these results demonstratedthe role of phagocytic cells, especially macrophages, for invivo presentation of particulate antigens. These particulateantigens represent an interesting approach for the developmentof new vaccines, and for the in vivo analysis of the role ofvarious antigen presenting cells in T cell activation and differentiation. 相似文献
54.
The optimal conditions for inactivation of Bordetella pertussis organisms with glutaraldehyde for the production of a safe and potent whole cell pertussis vaccine were investigated. Two bacterial harvests from B. pertussis strain 10536 were treated with glutaraldehyde, each with 0.025, 0.05 and 0.1% concentrations of glutaraldehyde for 10, 60 and 120 min. The nine types of glutaraldehyde-inactivated pertussis vaccine (GIPV) and conventional heat-inactivated pertussis vaccine (HIPV) preparations made from two bacterial harvests were comparatively evaluated for the mouse weight gain test (MWGT), potency, and the histamine-sensitization (HS) and leucocytosis-promoting-factor (LPF) tests. The minimum period for killing the B. pertussis organisms with glutaraldehyde was>10 min for 0.025%, 10 min for 0.05% and 5 min for 0.1% concentration. The average loss in opacity varied from 5 to 10% for GIPV preparations and was 14% for HIPV preparations. The GIPV preparations except those inactivated with 0.025% glutaraldehyde for 10 min (GIPV-A) were much less toxic than the HIPV preparations in the MWGT. The GIPV-A preparations did not pass the MWGT. The GIPV preparations were also much less toxic in HS and LPF tests than the HIPV preparation. The potency of GIPV preparations inactivated with 0.05% glutaraldehyde for 10 min (GIPV-D) was similar to that of HIPV preparations. The prolonged treatments with glutaraldehyde reduced the potency. The GIPV-D preparation with good potency and less toxicity was found to be inactivated with glutaraldehyde under optimal conditions. All the preparations were innocuous in the abnormal toxicity test. 相似文献
55.
56.
WHAN KOOK CHUNG KYU YONG CHOI CHANG DON LEE JIN WU CHUNG HEE SIK SUN KYU WON CHUNG BOO SUNG KIM CHUNG SIK CHUN KYOO HONG CHO SEUNG JO KIM 《Journal of gastroenterology and hepatology》1987,2(1):13-17
Different doses of hepatitis B virus vaccine—prepared by Korea Green Cross Corporation, were given to healthy infants born to HBsAg-negative mothers at birth, 1 and 6 months of age. A dose of 2 μg was administered intradermally in Group A and, in the three other groups, the vaccine was given intramuscularly (i.m.). An adequate follow-up observation was possible for 9 months after birth in 22, 25, 23 and 21 infants in Groups A, B, C and D, respecvely.
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization. 相似文献
Group C (5 μg, i.m.) produced seroconversion most rapidly, showing the highest rate (96%) at 9 months of age. The lowest seroconversion rate (5%) was found at the age of 1 month in Group A subjects, but the rate increased to 91% after a booster dose was given at 6 months of age.
While it can be concluded that a 5 μg i.m. dose of vaccine at 0, 1 and 6 months of age is optimum for the immunization of infants in efficacy and economy, a 2 μg intradermal dose can also be considered as an immunogenic and economical regimen, though the immune response is slower and a special technique is required for immunization. 相似文献
57.
Y. TRUDELLE A. BRACK A. DELMAS S. PEDOUSSAUT P. RIVAILLE 《Chemical biology & drug design》1987,30(1):54-60
Sequential poly(Arg-Thr-Lys-Pro) consisting mainly of the repeat of tuftsin Thr-Lys-Pro-Arg was synthesized by condensing the p-nitrophenyl ester of Arg(HCI)-Thr-Lys-(2-CI-Z)-Pro in the presence of HOBt . Two haptenic sequences of the Pre-S region of hepatitis B virus antigen (10–26 and 39–55) were prepared by solid phase and coupled to polytuftsin via glutaraldehyde. The peptides, either free or coupled to polytuftsin, were administrated to mice and the antisera were assayed by ELISA . Coupling the peptides to the polypeptide significantly improved the anti-peptide antibody titer in Freund complete adjuvant or in NaCI 0.9%. Cross-reaction between antibodies induced by the peptides and the native protein was also improved. Polytuftsin alone is very poorly immunogenic. 相似文献
59.
While two prophylactic HPV vaccines have been proven notably efficacious in clinical trials, the effectiveness of these vaccines at the population level remains to be evaluated. To lay the foundation for understanding the strengths and limitations of different endpoints for future effectiveness research, we present a comprehensive review of HPV-related clinical outcomes, including: (i) HPV type-specific positivity and persistence, (ii) Pap diagnoses (ASC-US, LSIL, and HSIL), (iii) histologic cervical cancer precursor lesions (i.e., CIN1, CIN2, and CIN3), (iv) invasive cervical cancer (ICC), (v) anogenital warts, (vi) recurrent respiratory papillomatosis (RRP), and (vii) other HPV-associated cancers (vulvar, vaginal, anal, penile, and oropharyngeal). While research on the vaccines’ effects on these HPV clinical outcomes in the general population is presently limited, numerous large trials will soon be completed, making a priori discussion of these potential outcomes especially urgent. Furthermore, population level systems to track HPV-associated clinical outcomes may need to be developed for HPV vaccine effectiveness evaluation. 相似文献
60.
目的检测以质粒pIRES为载体构建的带有全序列癌胚抗原(CEA)基因的核苷酸疫苗对机体特异性抗肿瘤免疫反应的激活效果。方法将CEA基因片段连接于真核表达质粒pIRES中,用肌肉注射方法接种核酸疫苗;检测CEA在小鼠肌肉组织中的表达情况及其对小鼠脾细胞CEA特异性细胞免疫反应的激活效果。结果小鼠经肌肉注射质粒后,免疫组化证实该核酸疫苗可在体内有效表达CEA;分子免疫检测显示注射后小鼠特异性淋巴细胞增值反应明显并且伴有自然杀伤细胞NK活性显著增高。结论实验所构建的核酸疫苗pIRESCEA可在体外及小鼠体内高效表达并表现出良好的细胞免疫原性。 相似文献